文献速递糖尿病

胰高血糖素-肝脏FGF21轴调控2型糖尿病小鼠模型的β细胞再生

Pancreatic alpha cell glucagon-liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes.
PubMed 文献 · Diabetologia · 2022-11-04

该研究在db/db小鼠和高脂饮食+链脲佐菌素诱导的2型糖尿病小鼠中,使用拮抗性GCGR单克隆抗体治疗,发现其改善血糖控制并增加胰岛数量和面积;机制上肝脏来源的FGF21介导了GCGR拮抗诱导的β细胞再生。

要点

  • GCGR单抗改善糖尿病小鼠血糖控制并增加胰岛数量和面积。
  • GCGR拮抗上调血浆和肝脏FGF21水平及肝脏Fgf21 mRNA和蛋白表达。
  • 阻断FGF21或肝脏特异性敲除Fgf21减弱GCGR单抗诱导的β细胞再生。

核心结论

  • 肝脏来源的FGF21参与GCGR拮抗诱导的2型糖尿病小鼠模型β细胞再生。

研究设计与样本

  • 在db/db小鼠和高脂饮食+链脲佐菌素诱导的2型糖尿病小鼠中给予拮抗性GCGR单克隆抗体治疗,评估代谢指标和胰岛细胞定量。

主要发现

  • GCGR单抗增加db/db小鼠胰岛数量(1.6±0.1 vs 0.8±0.1每mm²,p<0.001)和面积(2.5±0.2 vs 1.2±0.2%,p<0.001)。
  • GCGR单抗增加HFD+STZ小鼠胰岛数量(1.2±0.1 vs 0.5±0.1每mm²,p<0.01)和面积(1.0±0.1 vs 0.3±0.1%,p<0.01)。
  • GCGR单抗上调db/db小鼠血浆FGF21(661.5±40.0 vs 466.2±55.7 pg/ml,p<0.05)和HFD+STZ小鼠血浆FGF21(877.0±106.8 vs 445.5±54.0 pg/ml,p<0.05)。
  • GCGR单抗上调db/db小鼠肝脏Fgf21 mRNA(3.2±0.5 vs 1.8±0.1,p<0.05)和蛋白(2.0±0.2 vs 1.4±0.1,p<0.05),以及HFD+STZ小鼠肝脏Fgf21 mRNA(2.0±0.3 vs 1.0±0.2,p<0.05)和蛋白(1.6±0.1 vs 1.0±0.1,p<0.01)。
  • FGF21中和抗体减弱GCGR单抗处理小鼠血浆或肝细胞条件培养对β细胞身份相关基因mRNA的上调,且在FGF21中和抗体处理的db/db小鼠、Fgf21-/-和Fgf21Hep-/-糖尿病小鼠中GCGR单抗增加β细胞数量的效应减弱。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glucagon receptor (GCGR) antagonism ameliorates hyperglycaemia and promotes beta cell regeneration in mouse models of type 2 diabetes. However, the underlying mechanisms remain unclear. The present study aimed to investigate the mechanism of beta cell regeneration induced by GCGR antagonism in mice. METHODS: The db/db mice and high-fat diet (HFD)+streptozotocin (STZ)-induced mice with type 2 diabetes were treated with antagonistic GCGR monoclonal antibody (mAb), and the metabolic variables and islet cell quantification were evaluated. Plasma cytokine array and liver RNA sequencing data were used to screen possible mediators, including fibroblast growth factor 21 (FGF21). ELISA, quantitative RT-PCR and western blot were applied to verify FGF21 change. Blockage of FGF21 signalling by FGF21-neutralising antibody (nAb) was used to clarify whether FGF21 was involved in the effects of GCGR mAb on the expression of beta cell identity-related genes under plasma-conditional culture and hepatocyte co-culture conditions. FGF21 nAb-treated db/db mice, systemic Fgf21-knockout (Fgf21-/-) diabetic mice and hepatocyte-specific Fgf21-knockout (Fgf21Hep-/-) diabetic mice were used to reveal the involvement of FGF21 in beta cell regeneration. A BrdU tracing study was used to analyse beta cell proliferation in diabetic mice treated with GCGR mAb. RESULTS: GCGR mAb treatment improved blood glucose control, and increased islet number (db/db 1.6±0.1 vs 0.8±0.1 per mm2, p<0.001; HFD+STZ 1.2±0.1 vs 0.5±0.1 per mm2, p<0.01) and area (db/db 2.5±0.2 vs 1.2±0.2%, p<0.001; HFD+STZ 1.0±0.1 vs 0.3±0.1%, p<0.01) in diabetic mice. The plasma cytokine array and liver RNA sequencing data showed that FGF21 levels in plasma and liver were upregulated by GCGR antagonism. The GCGR mAb induced upregulation of plasma FGF21 levels (db/db 661.5±40.0 vs 466.2±55.7 pg/ml, p<0.05; HFD+STZ 877.0±106.8 vs 445.5±54.0 pg/ml, p<0.05) and the liver levels of Fgf21 mRNA (db/db 3.2±0.5 vs 1.8±0.1, p<0.05; HFD+STZ 2.0±0.3 vs 1.0±0.2, p<0.05) and protein (db/db 2.0±0.2 vs 1.4±0.1, p<0.05; HFD+STZ 1.6±0.1 vs 1.0±0.1, p<0.01). Exposure to plasma or hepatocytes from the GCGR mAb-treated mice upregulated the mRNA levels of characteristic genes associated with beta cell identity in cultured mouse islets and a beta cell line, and blockage of FGF21 activity by an FGF21 nAb diminished this upregulation. Notably, the effects of increased beta cell number induced by GCGR mAb were attenuated in FGF21 nAb-treated db/db mice, Fgf21-/- diabetic mice and Fgf21Hep-/- diabetic mice. Moreover, GCGR mAb treatment enhanced beta cell proliferation in the two groups of diabetic mice, and this effect was weakened in Fgf21-/- and Fgf21Hep-/- mice. CONCLUSIONS/INTERPRETATION: Our findings demonstrate that liver-derived FGF21 is involved in the GCGR antagonism-induced beta cell regeneration in a mouse model of type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Cui X, Feng J, Wei T, et al. Pancreatic alpha cell glucagon-liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes. Diabetologia. 2022. PMID: 36331598. doi:10.1007/s00125-022-05822-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。